{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T17:10:20Z","timestamp":1785431420790,"version":"3.56.0"},"reference-count":38,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81902569"],"award-info":[{"award-number":["81902569"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82573847"],"award-info":[{"award-number":["82573847"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82572347"],"award-info":[{"award-number":["82572347"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"award":["81902569"],"award-info":[{"award-number":["81902569"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"publisher"}]},{"award":["82573847"],"award-info":[{"award-number":["82573847"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"publisher"}]},{"award":["82572347"],"award-info":[{"award-number":["82572347"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"publisher"}]},{"name":"Excellent Youth Project of Heilongjiang Provincial Natural Science Foundation","award":["YQ2024H023"],"award-info":[{"award-number":["YQ2024H023"]}]},{"award":["YQ2024H023"],"award-info":[{"award-number":["YQ2024H023"]}],"id":[{"id":"https:\/\/ror.org\/04aqat463","id-type":"ROR","asserted-by":"publisher"}]},{"name":"Heilongjiang Province Postdoctoral Foundation","award":["LBH-Z22030"],"award-info":[{"award-number":["LBH-Z22030"]}]},{"name":"The Nn10 project at the Affiliated Cancer Hospital of Harbin Medical University","award":["Nn102024-01"],"award-info":[{"award-number":["Nn102024-01"]}]},{"award":["Nn102024-01"],"award-info":[{"award-number":["Nn102024-01"]}],"id":[{"id":"https:\/\/ror.org\/05jscf583","id-type":"ROR","asserted-by":"publisher"}]},{"name":"the Harbin Medical University Cancer Hospital Haiyan Foundation","award":["JJZD2024-24"],"award-info":[{"award-number":["JJZD2024-24"]}]},{"award":["JJZD2024-24"],"award-info":[{"award-number":["JJZD2024-24"]}],"id":[{"id":"https:\/\/ror.org\/01f77gp95","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: CDK4\/6 inhibitors induce G1\/S cell-cycle arrest in bladder cancer; however, adaptive resistance limits their therapeutic efficacy. The role of the m6A reader IGF2BP3 in regulating sensitivity to CDK4\/6 inhibition remains largely unknown. Methods: Transcriptomic profiling was performed in palbociclib-treated bladder cancer cell lines (T24, RT112, and UMUC-3) to identify m6A regulators associated with drug response. The expression and clinical significance of IGF2BP3 were evaluated using The Cancer Genome Atlas (TCGA) data and an independent clinical cohort. Gain- and loss-of-function assays were conducted to investigate the effects of IGF2BP3 on cell proliferation and cell-cycle progression. Mechanistic studies, including RNA-binding, mRNA stability, ubiquitination, and in vivo tumorigenesis assays, were performed to elucidate the underlying regulatory network. Results: IGF2BP3 was identified as the only m6A regulator differentially expressed following palbociclib treatment. IGF2BP3 expression was significantly elevated in bladder cancer tissues compared with normal tissues and was associated with poor prognosis and Ki67 positivity. Functionally, IGF2BP3 overexpression (OE) promoted G1\/S transition, increased MYC and downstream cell-cycle regulators, and partially rescued palbociclib-induced cell-cycle arrest, whereas IGF2BP3 knockdown (KD) suppressed cell proliferation in an MYC-dependent manner. Mechanistically, IGF2BP3 bound to MYC mRNA in an m6A-dependent manner and enhanced its stability. Furthermore, MKRN2 was identified as an E3 ubiquitin ligase that directly interacted with IGF2BP3, promoted its ubiquitination, and facilitated its proteasomal degradation. In vivo, MKRN2 co-overexpression attenuated IGF2BP3-driven tumor growth and synergized with palbociclib to maximally suppress tumor volume, reduce MYC and Ki67 expression, and induce apoptosis. Conclusions: These findings establish the MKRN2\u2013IGF2BP3\u2013MYC axis as a critical regulator of CDK4\/6 inhibitor sensitivity in bladder cancer. Targeting IGF2BP3 or enhancing MKRN2 activity may represent a promising strategy to overcome adaptive resistance and improve the therapeutic efficacy of CDK4\/6 inhibitors.<\/jats:p>","DOI":"10.3390\/cancers18132164","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T10:43:11Z","timestamp":1783334591000},"page":"2164","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["MKRN2-Mediated Degradation of IGF2BP3 Suppresses MYC and Enhances CDK4\/6 Inhibitor Sensitivity in Bladder Cancer"],"prefix":"10.3390","volume":"18","author":[{"given":"Qi","family":"Pan","sequence":"first","affiliation":[{"name":"Department of Urology, Shanghai General Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200080, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Shi","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Molecular Probe and Targeted Theranostics, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin 150001, China"},{"name":"Department of Urology, Harbin Medical University Cancer Hospital, Harbin 150001, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yubo","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Urology, Second Affiliate Hospital of Harbin Medical University, Harbin 150001, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianxi","family":"Yu","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Molecular Probe and Targeted Theranostics, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin 150001, China"},{"name":"Department of Urology, Harbin Medical University Cancer Hospital, Harbin 150001, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyu","family":"Bai","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, College of Pharmacy, Harbin Medical University, Harbin 150001, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoran","family":"Zhu","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Molecular Probe and Targeted Theranostics, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin 150001, China"},{"name":"Department of Urology, Harbin Medical University Cancer Hospital, Harbin 150001, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Urology, Second Affiliate Hospital of Harbin Medical University, Harbin 150001, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaowei","family":"Li","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Molecular Probe and Targeted Theranostics, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin 150001, China"},{"name":"Department of Urology, Harbin Medical University Cancer Hospital, Harbin 150001, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyi","family":"Liu","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Molecular Probe and Targeted Theranostics, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin 150001, China"},{"name":"Department of Urology, Harbin Medical University Cancer Hospital, Harbin 150001, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haonan","family":"Li","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Molecular Probe and Targeted Theranostics, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin 150001, China"},{"name":"Department of Urology, Harbin Medical University Cancer Hospital, Harbin 150001, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziqi","family":"Wang","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Molecular Probe and Targeted Theranostics, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin 150001, China"},{"name":"Department of Urology, Harbin Medical University Cancer Hospital, Harbin 150001, China"},{"name":"Department of Cystoscope Center, Harbin Medical University Cancer Hospital, Harbin 150001, China"},{"name":"Heilongjiang Provincial Key Laboratory of Basic Medical Sciences in Urology Cancer, Harbin Medical University Cancer Hospital, Harbin 150001, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhichao","family":"Tong","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Molecular Probe and Targeted Theranostics, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin 150001, China"},{"name":"Department of Urology, Harbin Medical University Cancer Hospital, Harbin 150001, China"},{"name":"Biobank, Harbin Medical University Cancer Hospital, Harbin 150001, China"},{"name":"Department of Urogenital Medical Oncology, Harbin Medical University Cancer Hospital, Harbin 150001, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrc3817","article-title":"Molecular biology of bladder cancer: New insights into pathogenesis and clinical diversity","volume":"15","author":"Knowles","year":"2015","journal-title":"Nat. Rev. Cancer."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","article-title":"Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer","volume":"171","author":"Robertson","year":"2017","journal-title":"Cell"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature12965","article-title":"Comprehensive molecular characterization of urothelial bladder carcinoma","volume":"507","author":"Weinstein","year":"2014","journal-title":"Nature"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"R77","DOI":"10.1186\/bcr2419","article-title":"PD 0332991, a selective cyclin D kinase 4\/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro","volume":"11","author":"Finn","year":"2009","journal-title":"Breast Cancer Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1158\/1078-0432.CCR-10-2307","article-title":"Expression of p16 and retinoblastoma determines response to CDK4\/6 inhibition in ovarian cancer","volume":"17","author":"Konecny","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ccell.2016.02.006","article-title":"Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4\/6 Inhibitors","volume":"29","author":"Goel","year":"2016","journal-title":"Cancer Cell"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.bcp.2019.02.017","article-title":"Palbociclib triggers apoptosis in bladder cancer cells by Cdk2-induced Rad9-mediated reorganization of the Bak.Bcl-xl complex","volume":"163","author":"Zhang","year":"2019","journal-title":"Biochem. Pharmacol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"253.e11","DOI":"10.1016\/j.urolonc.2023.01.010","article-title":"Identification of the KIF and MCM protein families as novel targets for combination therapy with CDK4\/6 inhibitors in bladder cancer","volume":"41","author":"Kositza","year":"2023","journal-title":"Urol. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Klein, F.G., Granier, C., Zhao, Y., Pan, Q., Tong, Z., Gschwend, J.E., Holm, P.S., and Nawroth, R. (2021). Combination of Talazoparib and Palbociclib as a Potent Treatment Strategy in Bladder Cancer. J. Pers. Med., 11.","DOI":"10.3390\/jpm11050340"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1158\/2159-8290.CD-18-0264","article-title":"The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial","volume":"8","author":"Cutts","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1158\/2159-8290.CD-15-0894","article-title":"Targeting CDK4 and CDK6: From Discovery to Therapy","volume":"6","author":"Sherr","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1038\/s41467-024-45796-w","article-title":"MYC induces CDK4\/6 inhibitors resistance by promoting pRB1 degradation","volume":"15","author":"Ma","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/s12943-019-1109-9","article-title":"Functions of N6-methyladenosine and its role in cancer","volume":"18","author":"He","year":"2019","journal-title":"Mol. Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"108613","DOI":"10.1016\/j.biopha.2019.108613","article-title":"The role of m6A RNA methylation in cancer","volume":"112","author":"Sun","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/s41556-018-0045-z","article-title":"Recognition of RNA N(6)-methyladenosine by IGF2BP proteins enhances mRNA stability and translation","volume":"20","author":"Huang","year":"2018","journal-title":"Nat. Cell Biol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/s13046-024-03120-w","article-title":"WTAP\/IGF2BP3 mediated m6A modification of the EGR1\/PTEN axis regulates the malignant phenotypes of endometrial cancer stem cells","volume":"43","author":"Wang","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.cell.2012.03.003","article-title":"MYC on the path to cancer","volume":"149","author":"Dang","year":"2012","journal-title":"Cell"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/s41419-024-06564-2","article-title":"LIN28B induced PCAT5 promotes endometrial cancer progression and glycolysis via IGF2BP3 deubiquitination","volume":"15","author":"Wang","year":"2024","journal-title":"Cell Death Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.bbrc.2020.05.112","article-title":"Ubiquitination of IGF2BP3 by E3 ligase MKRN2 regulates the proliferation and migration of human neuroblastoma SHSY5Y cells","volume":"529","author":"Jia","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1186\/s12967-024-05685-8","article-title":"Multi-omics analysis unveils the predictive value of IGF2BP3\/SPHK1 signaling in cancer stem cells for prognosis and immunotherapeutic response in muscle-invasive bladder cancer","volume":"22","author":"Wang","year":"2024","journal-title":"J. Transl. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"507","DOI":"10.7150\/ijbs.67770","article-title":"HPV E6\/E7 promotes aerobic glycolysis in cervical cancer by regulating IGF2BP2 to stabilize m(6)A-MYC expression","volume":"18","author":"Hu","year":"2022","journal-title":"Int. J. Biol. Sci."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/s41580-019-0168-5","article-title":"Reading, writing and erasing mRNA methylation","volume":"20","author":"Zaccara","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.7150\/ijbs.100518","article-title":"METTL3-mediated m6A modification of SLC7A11 enhances nasopharyngeal carcinoma radioresistance by inhibiting ferroptosis","volume":"21","author":"Dai","year":"2025","journal-title":"Int. J. Biol. Sci."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40659-025-00659-6","article-title":"Hsa_circ_0003611 hinders the transformation of mesenchymal stem cells into osteosarcoma cells through suppressing MYC by IGF2BP3 via m(6)A modification","volume":"59","author":"Zhang","year":"2025","journal-title":"Biol. Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.stem.2009.07.003","article-title":"The cell cycle and Myc intersect with mechanisms that regulate pluripotency and reprogramming","volume":"5","author":"Singh","year":"2009","journal-title":"Cell Stem Cell"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.ccell.2021.08.009","article-title":"Expanding control of the tumor cell cycle with a CDK2\/4\/6 inhibitor","volume":"39","author":"Hoffman","year":"2021","journal-title":"Cancer Cell"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.tibs.2025.07.009","article-title":"E3 ubiquitin ligases in signaling, disease, and therapeutics","volume":"50","author":"Ebadi","year":"2025","journal-title":"Trends Biochem. Sci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.1039\/D2CS00148A","article-title":"E3 ligase ligand chemistries: From building blocks to protein degraders","volume":"51","author":"Bricelj","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"217944","DOI":"10.1016\/j.canlet.2025.217944","article-title":"Dual regulation of FZD1\/7 by IGF2BP3 enhances stem-like properties and carboplatin resistance in triple-negative breast cancer","volume":"632","author":"Cai","year":"2025","journal-title":"Cancer Lett."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/s41585-023-00851-x","article-title":"RNA N(6)-methyladenosine modifications in urological cancers: From mechanism to application","volume":"21","author":"Yang","year":"2024","journal-title":"Nat. Rev. Urol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e011108","DOI":"10.1136\/jitc-2024-011108","article-title":"METTL3 promotes an immunosuppressive microenvironment in bladder cancer via m6A-dependent CXCL5\/CCL5 regulation","volume":"13","author":"Tong","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"147753","DOI":"10.1016\/j.ijbiomac.2025.147753","article-title":"USP10-stabilized IGF2BP3 promotes tumor growth via m(6)A-modified SKP2 mRNA in non-small-cell lung cancer","volume":"329","author":"Wang","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nrclinonc.2016.26","article-title":"Treating cancer with selective CDK4\/6 inhibitors","volume":"13","author":"Finn","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"R15","DOI":"10.1530\/ERC-18-0317","article-title":"Overcoming CDK4\/6 inhibitor resistance in ER-positive breast cancer","volume":"26","author":"Portman","year":"2019","journal-title":"Endocr.-Relat. Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Saranya, U., Shangavy, P., Devadass, J.M., Suresh, J., Jagadeesh Kumar, J.R., Girigoswami, A., and Girigoswami, K. (2025). Revolutionizing Cancer Vaccine: The Power of Advanced Nanotechnology. Chemistry, 7.","DOI":"10.3390\/chemistry7030097"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Zheng, R., Cai, Y., Ding, W., Yang, F., Ke, X., and Gao, Y. (J. Adv. Res., 2025). The landscape of genitourinary cancer vaccines: Clinical advances and future opportunities, J. Adv. Res., in press.","DOI":"10.1016\/j.jare.2025.11.049"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/13\/2164\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T04:49:13Z","timestamp":1783486153000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/13\/2164"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":38,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["cancers18132164"],"URL":"https:\/\/doi.org\/10.3390\/cancers18132164","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,6]]}}}